Last reviewed · How we verify

NCT05594420

Bleeding and Blood Transfusion in MVR

Status unknown Last updated 26 October 2022
What this trial tests

trial testing Mitral valve replacement in Mitral Valve Disease in 40 participants. Status unknown.

Timeline
1 December 2022
Primary endpoint
1 December 2023
1 January 2024

Quick facts

Lead sponsorAssiut University
StatusStatus unknown
Study typeOBSERVATIONAL
Enrollment40
Start date1 December 2022
Primary completion1 December 2023
Estimated completion1 January 2024

Drugs / interventions tested

Conditions studied

Sponsor

Assiut University

Who can join

Adults 18 to 80, any sex, with Mitral Valve Disease. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

To identify the best approach for mitral valve replacement to decrease risk of bleeding and restrict blood transfusion and its complication.

Publications & conference data

No peer-reviewed publications indexed yet for this trial.

Verify or expand the search:

Other trials of Mitral valve replacement

Trials testing the same drug.

Other recruiting trials for Mitral Valve Disease

Currently open trials in the same condition.

Other Assiut University trials

Trials by the same sponsor.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05594420.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing